On October 26-29, 2023, the 28th  Congress of Chinese Pediatric Society of Chinese Medical Association was held in Chengdu. This congress attracted more than 8000 authoritative experts in pediatrics and professionals in this field from all over the country, who had full and in-depth exchanges on different specialties of pediatrics. A total of 30 professional groups were set up, covering all the professional fields of pediatrics, aiming to give full play to the academic leadership in the field of pediatrics, provide high-quality evidence-based medical evidence for the diagnosis and treatment of related diseases, promote the breakthroughs of major problems or core key technologies affecting the health of children and adolescents, and jointly exchange and discuss the cutting-edge views, new technologies, new concepts and new methods in the field of pediatrics.

Opening Session of the 28th  Congress of Chinese Pediatric Society

This is the eighth time that H&H Group has participated in the National Pediatric Academic Conference. During the conference, BINC, a non-profit academic organization under the H&H Group, held a satellite conference on "Scientific Evidence-based Probiotics for Early Life Health". Professor Xu Chundi, Chief Physician of the Department of Pediatrics at Ruijin Hospital of Shanghai Jiaotong University, was invited to host the satellite meeting, and two authoritative clinical experts were invited to bring exciting academic sharing, among which the innovative research on probiotics and infant immunity and infant colic attracted wide attention from the experts present. At the same time, BINC also set up a booth to comprehensively display the Hershey's series of infant probiotics, milk powder and nutritional products, which aroused the attentions and extensive exchanges among the attending experts.

Biostime's Scientific Research Achievements Receive Attention from Participating Experts

Hu Ruibiao, Scientific R&D Director of BNC (Business Unit of Baby Nutrition and Care) China of H&H Group, brought the opening speech to the satellite meeting. He mentioned that since its establishment in 1999, BNC, a brand of the H&H Group, has been committed to the research and development of infant and child nutrition products for more than two decades, and has always adhered to scientific validation. Among them, infant immunity and intestinal health have always been the focus of Hexogen's attention. Biostime has carried out a series of innovative research projects on breast milk immune active ingredients and probiotics, and applied the research results in product development to guard the immune health of infants and children of every generation.

Biostime's special satellite meeting site

Host, Chief Physician, Department of Pediatrics, Ruijin Hospital, Shanghai Jiaotong University, China

Prof. Xu Chundi

This satellite meeting firstly invited Prof. Zhang Lin, Chief Physician of Pediatrics Department of the Third Hospital of Hebei Medical University, to present the report "Innovation and Empirical Evidence: Exploring the Healthy Role of Probiotics on the Immune System of Infants and Young Children", which systematically discussed the development of the immune system of infants and young children and its correlation with the intestinal micro-ecology, and introduced in detail the clinical research and industrial application of probiotics in the immune health of infants and young children.

Prof. Zhang Lin, Chief Physician of Pediatrics Department of the Third Hospital of Hebei Medical University

It is introduced in the report that a balanced immune system is the foundation for maintaining the health of the organism, and the immune system of infants is not yet mature and does not have stable immune function when they are just born. The establishment of intestinal flora is closely related to the development of the immune system. Supplementation of probiotics, especially Lactobacillus and Bifidobacterium, during infancy can help the development and maturation of intestinal flora and the construction of the immune system. Several clinical studies have demonstrated that probiotic strains that can be used in infant foods - Bifidobacterium infantis R0033, Bifidobacterium bifidum R0071, and Lactobacillus suis R0052 - can help to increase fecal immunoglobulin sIgA levels, reduce the risk of wintertime infections, and increase serum immunoglobulins to support infant immune health. Bifidobacterium infantis is the dominant flora in the infant gut and is able to metabolize all HMO structures, is better adapted, and is more likely to colonize the infant gut.

In addition, breast milk oligosaccharides and lactoferrin are important immunologically active components. Among them, 2'-fucosyl lactose (2'-FL) is the most abundant HMO in breastmilk and has been approved for use in infant foods. The Scientific Consensus on Breastmilk Oligosaccharides (HMOs), organized and drafted by the Chinese Institute of Food Science and Technology with the in-depth participation of H&H Group, has also been released, promoting the application and industrial development of HMOs in China. Up to now, H&H Group has applied for more than 30 HMO-related invention patents in China, the United States, Australia, Europe and other countries and regions, continuing to empower HMO innovative research and technology.

The H&H Group always adheres to scientific validation and applies the research results of probiotics, HMO and lactoferrin to product development. Its high-end infant nutrition and health brand, Biostime, has innovatively developed a series of products called "Probiotics+", including Biostime Original Probiotic, HMO Probiotic, and HMO Lactoferrin Probiotic products, to comprehensively support the immune and intestinal health of infants. The satellite conference also featured Chengdu's newest and most innovative probiotic product, "Probiotics+".

Professor Chen Ke, Director of Clinical Nutrition Department of Chengdu Women and Children's Center Hospital, was invited to share his insights into the application of probiotics in infant colic from the perspective of intestinal micro-ecology, which comprehensively explained the impact of intestinal flora disorders on infant colic, and enumerated the clinical improvement and innovative application of probiotics in infant colic.

Professor Chen Ke, Director of Clinical Nutrition Department of Chengdu Women and Children's Center Hospital

Prof. Chen mentioned that infantile colic is a functional gastrointestinal disorder that is prevalent in infants and is mainly characterized by prolonged and repeated crying and/or irritability or agitation without any obvious triggers, which is difficult to appease and cannot be stopped or relieved. Infantile colic may have adverse effects on the near- and long-term health of both the infant and the family, such as an increased risk of irritable bowel syndrome IBS in childhood. Studies have shown that the intestinal flora of infants with colic is different from that of healthy infants, with decreased levels of Lactobacillus and Bifidobacterium, increased colonization of gas-producing bacteria and excessive gas production from fermentation that dilates the intestinal tract, and gram-negative bacteria inducing inflammation in the intestinal tract, which may result in a dysbiosis that can lead to colic.

Clinical studies have shown that Bifidobacterium longum СECТ 7894 and Pentosaccharomyces cerevisiae CECT 8330 isolated from the intestinal tract of healthy infants significantly reduce crying and irritability, improve defecation and stool characteristics in colicky infants; help to improve functional gastrointestinal disorders in infants; regulate the intestinal flora, increase the diversity of the bacterial flora, and increase the level of bifidobacteria. In vitro studies have shown that Bifidobacterium longum СECТ 7894 and Pentosaccharomyces cerevisiae CECT 8330 can inhibit the growth of pathogenic bacteria, especially gas-producing bacteria, and can induce macrophages to produce the anti-inflammatory factor IL-10.

Based on the results of the innovative research, the H&H Group has developed colic probiotic drops with Bifidobacterium longum СECТ 7894 and Pentosaccharomyces cerevisiae CECT 8330, which are aimed at improving colic and intestinal health of infants by regulating the microecology of the intestinal tract.

Professor Ping Dong, Associate Chief Physician of the Department of Child Health, Pediatrics Hospital of Fudan University, a collaborating expert of the BINC Fund project, shared a report on "Preliminary Research Report on the Influence of Fatty Acid Esters of Hydroxy Fatty Acids (FAHFAs) in Breast Milk on Infant and Toddler Growth and Development", which is aimed at exploring the mechanism of the generation of FAHFAs in breast milk, the factors influencing them, and their roles they play in the growth and development of children in the early postnatal period.

Professor Ping Dong, a collaborating expert of the BINC Fund project

Associate Chief Physician of the Department of Child Health, Pediatrics Hospital of Fudan University

The report describes that FAHFAs are a large group of endogenous lipids present in mammals. Studies have shown that some FAHFAs, such as palmitate of hydroxystearic acid, have significant anti-inflammatory properties in humans, while other polyunsaturated FAHFAs, such as docosahexaenoic acid (DHA)-derived FAHFAs, may be important lipid messengers mediating immune-metabolic processes. Recent breast milk lipidomics studies have confirmed the presence of FAHFAs in human milk, and researchers speculate that they may be important bioactive components exported to infants through breast milk, with the potential to play important roles in growth and development, immunity and metabolic regulation. The project is currently underway, and we look forward to sharing further research results with scholars from all walks of life in the future.

Focus on science, care for mothers and babies! The the  Congress of Chinese Pediatric Society provided a valuable academic exchange platform for experts in the field of maternal and child nutrition and health to share the latest research results and cutting-edge information with the society, and to further promote academic research and applied practice in the fields of nutrition, nursing, and psychology. In the future, BINC will continue to work together with authoritative experts and scholars at home and abroad to deepen scientific research and academic exchanges in the field of maternal and child health, and jointly promote the vigorous development of maternal and child health!